Experienced Merger And Acquisition Attorneys

Mergers and acquisitions are extremely complex business transactions that require careful analysis and execution at every stage. There can be regulatory issues that need to be considered in many cases, particularly in transactions involving companies in FDA-regulated industries.

Providing FDA Regulatory Compliance And Due Diligence Support

The lawyers at the law firm of Eric F. Greenberg, P.C., provide experienced representation in mergers and acquisitions and related issues. Our extensive experience in the areas of food and drug law and packaging law allows us to provide invaluable insight into the unique issues that need to be considered in these matters.

A timely and thorough assessment of FDA compliance risk can help you avoid a bad deal, reflect risk in your pricing decisions or just help you gain an early understanding of what is needed to keep compliant in the FDA environment. From pre-audit reviews of your compliance program to support in any aspect of the due diligence process, we are prepared to provide the attentive service you require.

Contact Our Office To Discuss Your Needs With An Attorney

Contact our Chicago, Illinois, office to learn more about our mergers and acquisitions and due diligence support services. You can reach us by phone at 312-977-4647 or contact us via email.

GRAS Goes to Congress

GRAS Goes to Congress

By Eric F. Greenberg, Attorney-at-law

Remember that whole business involving NGOs and other folks objecting to the legal system that allows companies to self-determine that their uses of substances are Generally Recognized As Safe (“GRAS”)? And remember how some groups had gone to court to get the system declared unlawful, but late last year the court ruled against them? Well, there’s a new chapter to this story. Now, some members of Congress have proposed a bill that would make changes to the law to address those very same objections.

The GRAS pathway to clearance of the use of substances in packaging and in food is crucially important, and this proposed law has the potential to make enormous changes in various legal obligations. For that reason, packagers should keep a close eye on this latest chapter in the ongoing debate over the policy issues surrounding the GRAS system.

In my view, addressing the complaints we’ve heard for years about the GRAS program required changes in the law, so at least the objectors are in the correct forum. There’s been so much criticism of the Food and Drug Administration lately, what with its slow reaction to the infant formula contamination problem, on top of its handling of issues relating to heavy metals in baby food and various complaints about its handling of COVID and other drug approvals, for some examples. But when it comes to the GRAS program, it’s always seemed that most of the objectors’ objections were better directed at Congress than at FDA.

You have questions, We have answers. Request a consult.

Our Office Location

303 East Wacker Drive Suite 305
Chicago, IL 60601

Phone: 312-977-4647